Procter & Gamble Health Beheer
Beheer criteriumcontroles 2/4
Momenteel beschikken wij niet over voldoende informatie over de CEO.
Belangrijke informatie
Milind Thatte
Algemeen directeur
₹32.2m
Totale compensatie
| Percentage CEO-salaris | 100.0% |
| Dienstverband CEO | 6.6yrs |
| Eigendom CEO | n/a |
| Management gemiddelde ambtstermijn | geen gegevens |
| Gemiddelde ambtstermijn bestuur | 5.4yrs |
Recente managementupdates
Recent updates
Procter & Gamble Health (NSE:PGHL) Is Due To Pay A Dividend Of ₹60.00
Nov 15
Risks To Shareholder Returns Are Elevated At These Prices For Procter & Gamble Health Limited (NSE:PGHL)
Nov 05Procter & Gamble Health (NSE:PGHL) Has Announced A Dividend Of ₹60.00
Sep 28Procter & Gamble Health (NSE:PGHL) Has Announced A Dividend Of ₹60.00
Aug 27Earnings Not Telling The Story For Procter & Gamble Health Limited (NSE:PGHL)
Jun 08Weak Statutory Earnings May Not Tell The Whole Story For Procter & Gamble Health (NSE:PGHL)
Feb 14Procter & Gamble Health (NSE:PGHL) Has Announced That It Will Be Increasing Its Dividend To ₹50.00
Sep 29Procter & Gamble Health's (NSE:PGHL) Shareholders Will Receive A Bigger Dividend Than Last Year
Sep 10Procter & Gamble Health's (NSE:PGHL) Shareholders Will Receive A Bigger Dividend Than Last Year
Aug 27A Look At The Fair Value Of Procter & Gamble Health Limited (NSE:PGHL)
Mar 30We Think The Compensation For Procter & Gamble Health Limited's (NSE:PGHL) CEO Looks About Right
Nov 17Procter & Gamble Health (NSE:PGHL) Has Announced That Its Dividend Will Be Reduced To ₹11.50
Oct 23Procter & Gamble Health's (NSE:PGHL) Dividend Will Be Reduced To ₹11.50
Oct 09Procter & Gamble Health's (NSE:PGHL) Problems Go Beyond Weak Profit
Feb 16Do Procter & Gamble Health's (NSE:PGHL) Earnings Warrant Your Attention?
Oct 04Here's Why I Think Procter & Gamble Health (NSE:PGHL) Is An Interesting Stock
May 10Would Procter & Gamble Health Limited (NSE:PGHL) Be Valuable To Income Investors?
Mar 23Is Weakness In Procter & Gamble Health Limited (NSE:PGHL) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?
Mar 02Should You Be Adding Procter & Gamble Health (NSE:PGHL) To Your Watchlist Today?
Jan 31Here's What Procter & Gamble Health Limited's (NSE:PGHL) Shareholder Ownership Structure Looks Like
Jan 10
Is Procter & Gamble Health Limited (NSE:PGHL) An Attractive Dividend Stock?
Dec 19Is Procter & Gamble Health Limited's (NSE:PGHL) Latest Stock Performance A Reflection Of Its Financial Health?
Dec 01Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | ₹2b |
| Jun 30 2024 | ₹32m | ₹32m | ₹2b |
| Mar 31 2024 | n/a | n/a | ₹2b |
| Dec 31 2023 | n/a | n/a | ₹2b |
| Sep 30 2023 | n/a | n/a | ₹2b |
| Jun 30 2023 | ₹25m | ₹25m | ₹2b |
| Mar 31 2023 | n/a | n/a | ₹2b |
| Dec 31 2022 | n/a | n/a | ₹2b |
| Sep 30 2022 | n/a | n/a | ₹2b |
| Jun 30 2022 | ₹39m | ₹39m | ₹2b |
| Mar 31 2022 | n/a | n/a | ₹2b |
| Dec 31 2021 | n/a | n/a | ₹1b |
| Sep 30 2021 | n/a | n/a | ₹2b |
| Jun 30 2021 | ₹32m | ₹32m | ₹2b |
| Mar 31 2021 | n/a | n/a | ₹2b |
| Dec 31 2020 | n/a | n/a | ₹2b |
| Sep 30 2020 | n/a | n/a | ₹2b |
| Jun 30 2020 | ₹17m | ₹26m | ₹2b |
| Mar 31 2020 | n/a | n/a | ₹2b |
| Dec 31 2019 | n/a | n/a | ₹2b |
| Sep 30 2019 | n/a | n/a | ₹1b |
| Jun 30 2019 | n/a | n/a | ₹1b |
| Mar 31 2019 | n/a | n/a | ₹1b |
| Dec 31 2018 | ₹20m | ₹13m | ₹1b |
Compensatie versus markt: De totale vergoeding ($USD 381.84K ) Milind } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de Indian markt ($USD 354.64K ).
Compensatie versus inkomsten: De beloning van Milind is het afgelopen jaar met meer dan 20% gestegen, terwijl de winst van het bedrijf met meer dan 20% is gedaald.
CEO
Milind Thatte (55 yo)
6.6yrs
Tenure
₹32,234,000
Compensatie
Mr. Milind Vasant Thatte, M.Pharm.Sci., M.B.A., has been Managing Director and Executive Director of Procter & Gamble Health Limited (formerly known as Merck Limited) since April 1, 2018. Mr. Thatte had a...
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| MD & Executive Director | 6.6yrs | ₹32.23m | geen gegevens | |
| CFO, Finance Head & Executive Director | 1.6yrs | ₹24.94m | geen gegevens | |
| Non-Executive Independent Chairman of the Board | 40.8yrs | ₹2.33m | 0.036% ₹ 30.8m | |
| Non-Executive Independent Director | 3yrs | ₹2.20m | geen gegevens | |
| Non-Executive Independent Director | 9.8yrs | ₹2.18m | geen gegevens | |
| Non-Executive Director | 5.4yrs | geen gegevens | geen gegevens | |
| Non-Executive Director | 1.6yrs | geen gegevens | geen gegevens |
5.4yrs
Gemiddelde duur
61.5yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van PGHL wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.4 jaar).